会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • METHODS FOR GENERATING AND USING STEM CELL PROFILES
    • WO2007103763A3
    • 2007-09-13
    • PCT/US2007/063123
    • 2007-03-02
    • BIO REGENERATE, INC.TREVES, Ami
    • TREVES, Ami
    • C12N5/08
    • A method for phenotypical and functional characterization of various populations of stem and progenitor cells from cell samples, such as tissue samples is disclosed. In one aspect, the method can be used to identify the status of these cells and their functions in individuals. The method, when applied to blood tissue, can include a step of enriching stem cell lineages that are commonly found in both the bone marrow and peripheral blood: the hematopoietic, endothelial and mesenchymal stem/progenitor cells. The variety and population of stem cells can be identified by analysis of cell markers for several defined stem cell and lineage committed markers and by analysis of characteristic ex vivo self renewal potential. Such techniques can be used to obtain a functional profile of stem/progenitor populations for each cell sample, and for various clinical conditions. The profile can also be associated with and add value to the storage and banking business of stem cells. Profiles and consecutive profiles for individuals can be included in a database along with health characteristics of the individuals. The database can be used for patient follow-up or scientific reference. Database profiles for certain populations may serve for statistical, epidemiological and health evaluations.
    • 3. 发明申请
    • COMPOSITIONS AND METHODS FOR REDUCING CELLULAR FAT AND FOR PREDICTING CARDIAC TOXICITY AND UPON TREATMENT WITH TYROSINE KINASE INHIBITORS
    • 用酪蛋白激酶抑制剂减少细胞脂肪和预测心脏毒性并治疗的组合物和方法
    • WO2007101191A2
    • 2007-09-07
    • PCT/US2007/062871
    • 2007-02-27
    • TARGETED MOLECULAR DIAGNOSTICS, LLCBACUS, Sarah, S.
    • BACUS, Sarah, S.
    • G01N33/5061G01N33/5091G01N2333/4706G01N2333/81G01N2800/52
    • Methods are disclosed for determining whether organ toxicity, particularly cardiotoxicity, will occur in a patient selected for treatment with various kinase inhibitors, such as tyrosine kinase inhibitors, more particularly erbB inhibitors such as Herceptin. In addition, methods are disclosed for determining whether a potential drug is likely to produce a cardiotoxic effect. The methods involve analyzing lipid levels or the expression fatty acid oxidation enzymes, pAMP activated protein kinase, glucose uptake, to determine whether a fatty acid oxidation disorder is present. The identification of a fatty acid oxidation disorder can be used as a predictor of toxicity, especially cardiac toxicity, and as an indication that organ function should be carefully monitored if a drug such as a tyrosine kinase inhibitor is administered. Methods are also disclosed for protecting organs from metabolic stress and for the treatment of cells, such as adipocytes, to reduce their lipid content.
    • 公开了用于确定选择用各种激酶抑制剂治疗的患者(例如酪氨酸激酶抑制剂,更特别是erbB抑制剂如赫赛汀)是否会发生器官毒性,特别是心脏毒性的方法。 另外,公开了用于确定潜在药物是否可能产生心脏毒性效应的方法。 该方法涉及分析脂质水平或表达脂肪酸氧化酶,pAMP活化蛋白激酶,葡萄糖摄取,以确定是否存在脂肪酸氧化障碍。 脂肪酸氧化障碍的鉴定可以用作毒性的预测指标,尤其是心脏毒性,并且指出如果施用诸如酪氨酸激酶抑制剂的药物,应仔细监测器官功能。 还公开了用于保护器官免受代谢应激和用于治疗细胞(例如脂肪细胞)以降低其脂质含量的方法。
    • 4. 发明申请
    • PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HIGHLY LIPOPHILIC SULFHYDRYL COMPOUNDS
    • 药物组合物及使用高亲液性硫酸化合物的方法
    • WO2007073560A2
    • 2007-06-28
    • PCT/US2006/062418
    • 2006-12-20
    • RND PHARMACEUTICALS, INC.GATELY, StephenWEST, Robert
    • GATELY, StephenWEST, Robert
    • C07F7/0818C07D213/60C07D213/75C07F7/0814
    • Novel compositions of silicon-containing sulfhydryl compounds, their preparation and use in methods for treating disease are described. Silicon confers lipophilicity that can enhance the penetration of the silicon derivative sulfhydryl compounds across the gut wall, cell membranes and blood brain barrier, thus improving therapeutic properties including bioavailability, metabolism, and/or pharmacokinetics. The organosilyl group provides compounds having improved pharmacokinetics. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for treatment of diseases and other maladies or conditions and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    • 描述了含硅巯基化合物的新型组合物,其制备方法和用于治疗疾病的方法中的用途。 硅赋予亲脂性,其可以增强硅衍生物巯基化合物穿过肠壁,细胞膜和血脑屏障的渗透,从而改善治疗特性,包括生物利用度,代谢和/或药代动力学。 有机甲硅烷基提供具有改善的药代动力学的化合物。 本发明包括新型化合物,类似物,前药和药学上可接受的盐,用于治疗疾病和其它疾病或病症等的药物组合物和方法。 本发明还涉及制备这些化合物的方法以及在这些方法中有用的中间体。